J&J's Vitros Lab Diagnostics Systems Expand Market Access, Drive Sales
This article was originally published in The Gray Sheet
Executive Summary
Ortho-Clinical Diagnostics' Vitros 5600 and Vitros 3600 next-generation laboratory diagnostic systems will double the size of the market the Johnson & Johnson division addresses from $4.6 billion to $9.8 billion, according to the company
You may also be interested in...
J&J/DePuy's Ceramic-On-Metal Hip Is Approvable With Conditions - Panel
Johnson & Johnson/DePuy's CoMplete ceramic-on-metal acetabular hip system should be approved by FDA, according to the agency's Orthopedic and Rehabilitation Devices Panel
J&J’s Computer-Assisted Sedation System Gets FDA Panel Nod
Ethicon Endo-Surgery's Sedasys computer-assisted personalized sedation system should be approved by FDA, as long as labeling requires a three-person team to be present during its use, according to the agency's Anesthesiology and Respiratory Therapy Devices panel
J&J’s Vitros 5600 system receives 510(k)
Ortho-Clinical Diagnostics, a Johnson & Johnson company, plans in the fourth quarter to launch its Vitros 5600 next-generation laboratory diagnostics system, following receipt of 510(k) clearance Oct. 24. The device integrates clinical chemistry and immunoassay testing while incorporating "innovations" such as "sample-centered" processing and a small footprint, the firm explains. It can perform more than 100 different chemistry, immunoassay and infectious disease assays